(MYGN) Myriad Genetics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Myriad Genetics, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategies and how they drive market positioning and sales; it’s designed for fast marketing research and strategic planning. The page shows a real preview/sample of the report so you can review style and content—purchase the full version to get the complete ready-to-use analysis.
Product
MyRisk Hereditary Cancer Test
MyRisk Hereditary Cancer Test is Myriad Genetics, Inc.'s core oncology test: a 48-gene germline DNA sequencing panel for inherited cancer risk. It screens across multiple tumor types to find hereditary cancer predisposition early. That helps clinicians make faster screening, prevention, and family-testing decisions.
BRACAnalysis CDx
BRACAnalysis CDx is Myriad Genetics, Inc.'s FDA-approved companion diagnostic for BRCA1 and BRCA2 variants, used in metastatic breast, ovarian, pancreatic, and prostate cancers to help pick treatment, including PARP inhibitors. BRCA1/2 mutations appear in about 5%-10% of breast cancers and 10%-15% of ovarian cancers, which supports steady clinical demand. The test links diagnosis to therapy, making it a core precision-oncology product for Myriad Genetics, Inc.
MyChoice CDx
MyChoice CDx is a tumor-based homologous recombination deficiency assay that helps guide ovarian cancer care, where the American Cancer Society estimated 20,890 new U.S. cases and 12,730 deaths in 2025. It supports precision medicine by identifying patients more likely to benefit from targeted therapies, including PARP inhibitors, which makes the test clinically useful at the point of treatment choice. For Myriad Genetics, Inc., the product is a differentiated diagnostic asset built for companion-diagnostic use in a high-need oncology market.
Prolaris and EndoPredict
Prolaris and EndoPredict are RNA expression-based prognostic tests that help estimate tumor aggressiveness in prostate and breast cancer, so physicians can match treatment intensity to disease biology. Myriad Genetics positions them as decision tools that can reduce overtreatment and support more precise care.
These tests sit in the high-value oncology diagnostics segment, where each result can shape surgery, radiation, or hormone therapy choices. In Myriad Genetics latest reported mix, oncology products remain a core revenue driver.
- Prolaris: prostate cancer prognosis
- EndoPredict: breast cancer prognosis
- RNA expression analysis
- Guides treatment intensity
Prequel, Foresight, GeneSight
Prequel is a prenatal screening test, Foresight is a carrier screen, and GeneSight is a psychotropic medication test. Together they push Myriad Genetics beyond oncology into women’s health and mental health, covering decision points from preconception to treatment selection.
This broader mix widens the addressable patient base and helps Myriad serve multiple clinicians, not just oncologists. GeneSight has been ordered for over 2 million patients, showing scale in medication guidance.
That portfolio also adds cross-sell value: one Company can touch family planning, pregnancy risk, and psychiatric prescribing. For the 4P mix, the product line is a clear differentiator because it spans the full patient lifecycle.
- Prequel: prenatal screening
- Foresight: carrier screening
- GeneSight: psychotropic guidance
- Reach: preconception to psychiatry
Myriad’s Cancer Tests Lead, With Psychiatry and Reproductive Health Growing
Myriad Genetics, Inc. product mix is led by oncology diagnostics: MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict.
These tests cover inherited risk, companion diagnostics, and prognosis, helping guide treatment for breast, ovarian, prostate, and pancreatic cancer.
GeneSight, Prequel, and Foresight widen the portfolio into psychiatry and reproductive health.
| Product | Use |
|---|---|
| MyRisk | Hereditary cancer |
| GeneSight | Psychiatry |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Myriad Genetics, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses Myriad Genetics’ 4Ps into a quick, clear snapshot that helps teams spot positioning gaps fast.
Reference Sources
Provides a concise, traceable bibliography of primary industry reports, regulatory filings, and peer-reviewed studies to verify Myriad Genetics’ market, pricing, and clinical claims.
Place
United States clinical market
Myriad Genetics, Inc. sells into the United States clinical market through physicians, hospitals, and lab workflows, not retail shelves. Its tests are ordered in care settings across all 50 states, so access depends on clinician demand, reimbursement, and payer contracts. This channel fits genetic testing, where the "place" is the clinical pathway from order to result.
International market access
Myriad Genetics, Inc. sells in international markets, which extends its precision-medicine reach beyond the U.S. In FY2025, the Company reported $837.5 million in revenue, and foreign demand can add growth when local rules allow it. Access still depends on country-by-country regulatory clearance and reimbursement, so uptake can vary a lot by market.
Physician and specialist channels
Myriad Genetics routes most testing through physicians, oncologists, OB-GYNs, and mental health prescribers, so the product sits inside the care path, not after it. This fits a clinical market where test orders are tied to treatment choices, and it helps place testing where the decision happens: at the point of care.
Health system and lab partnerships
Myriad Genetics, Inc. uses health system and lab partnerships to widen access to germline and somatic tumor testing. Alliances with Illumina and Intermountain Precision Genomics support broader test reach, stronger workflow fit, and faster market entry across provider networks.
These ties help Myriad keep its tests close to the point of care, which can lift adoption in oncology and hereditary cancer screening. The model matters because myRisk and myChoice CDx depend on both clinical trust and lab scale.
- Illumina expands testing capability
- Intermountain boosts provider access
- Supports germline and somatic testing
Centralized laboratory model
Myriad Genetics, Inc. uses a centralized laboratory model for most genetic tests, which keeps complex molecular diagnostics in specialized lab sites and supports tighter quality control, faster turnaround, and consistent reporting. This setup fits high-complexity assays better than a wide local-network model because one lab platform can standardize workflow and review.
It also helps Myriad Genetics, Inc. scale test volumes while keeping results comparable across indications like hereditary cancer and prenatal testing. In a diagnostics business, that consistency matters as much as speed.
- Centralized processing improves quality control
- Standardized reporting supports clinician trust
- Best fit for complex molecular tests
Myriad Genetics: Care-Path Testing Drives $837.5M Revenue
Myriad Genetics, Inc. places testing inside the care path: physicians and health systems order tests, and results return through centralized labs. That model supported FY2025 revenue of $837.5 million, while U.S. access, reimbursement, and international rules still shape where demand converts to sales.
| Place factor | FY2025 data |
|---|---|
| Revenue | $837.5 million |
| Access model | Physician and health system orders |
| Operations | Centralized laboratory delivery |
Preview the Actual Deliverable
Myriad Genetics, Inc. Reference Sources
The preview shown here is the actual Myriad Genetics, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it’s the full, editable document covering Product, Price, Place, and Promotion with actionable insights and examples tailored to Myriad’s diagnostics business.
Promotion
Clinical evidence marketing
Myriad Genetics promotes its tests with clinical utility data and peer-reviewed science, which matters because physicians and payers often want proof that a test changes care, not just that it works in the lab. Its messaging centers on decision support and patient impact, helping clinicians choose treatment sooner and with more confidence. In diagnostics, evidence drives reimbursement and adoption, so this proof-first approach is a core sales tool.
Physician education programs
Physician education is Myriad Genetics, Inc."s main promotion tool because its tests are ordered by healthcare professionals. In oncology, prenatal care, and psychiatric pharmacogenomics, training on indications and result use matters: 1 in 8 U.S. women face breast cancer, and PGx can cut adverse drug reactions by 30% to 40%.
Strategic alliance announcements
Myriad Genetics, Inc. uses strategic alliances as promotion, with at least 2 visible partners, Illumina and Intermountain Precision Genomics, to boost credibility and reach. These deals help signal product integration, which can speed adoption in clinical labs and broaden market access. For investors, partner-led promotion matters because it supports trust without heavy brand spend.
Medical congress presence
Myriad Genetics, Inc. can use medical congresses to share fresh clinical data and study results with specialists who shape test use. Major meetings matter: ASCO 2025 drew more than 40,000 oncology professionals, giving Myriad Genetics, Inc. direct access to high-impact prescribers.
This channel supports trust, speeds adoption, and keeps the portfolio visible beside peer-reviewed science.
- Shows new data fast
- Reaches key specialists
- Supports test adoption
Public relations and investor communications
Myriad Genetics, Inc. uses press releases, earnings materials, and corporate updates to keep investors informed on product launches, reimbursement progress, and strategy. In its 2025 reporting cycle, this channel mix helped support market awareness and credibility as the company worked through payer coverage and growth updates. One line: it is built to move news fast and keep stakeholders aligned.
- Press releases on launches
- Earnings updates on growth
- Reimbursement progress for coverage
- Signals strategic direction clearly
Myriad’s Evidence-Led Promotion Drives Reimbursement and Adoption
Myriad Genetics, Inc. uses evidence-led promotion: physician education, peer-reviewed data, congresses, and payer-facing proof. In 2025, it reported $837.5M revenue, so sales support matters; strong reimbursement and clinical adoption are the core promotion goals.
| Channel | Role | 2025 data |
|---|---|---|
| Medical evidence | Build trust | $837.5M revenue |
Price
Test-by-test pricing
Myriad Genetics’ pricing is test-by-test, not one flat rate: each assay is set by complexity, clinical use, and payer coverage, so economics differ across hereditary cancer, prenatal, and pharmacogenomic tests. In FY2025, that mix and reimbursement flow mattered more than list price, with realized price varying by assay. This is a per-test model, not a bundle.
Payer reimbursement
Payer reimbursement is the main price lever for Myriad Genetics, Inc., because insurer coverage decides whether patients pay near $0 or face hundreds of dollars in out-of-pocket costs. In molecular diagnostics, medical-necessity rules vary by plan and can change access fast, so coverage is as important as list price.
Myriad Genetics, Inc. must win favorable payer policies to protect volume and margins. Recent U.S. payer shifts in genetic testing have tightened prior-authorization and evidence demands, which makes reimbursement the real price gatekeeper.
That means the same test can sell at one price but clear at another, based on payer contracts, coding, and clinical-policy reviews.
Insurance and network contracts
Myriad Genetics, Inc. prices tests through negotiated payer contracts, so network status can sharply change what patients pay and what the company actually collects. In-network coverage usually lowers out-of-pocket costs and makes tests easier to order, while out-of-network claims can mean higher patient bills and lower realized revenue. Contracted reimbursement is key to broader adoption because it gives doctors and payers clearer payment rules.
Self-pay and patient support
Myriad Genetics, Inc. can face self-pay demand when payer coverage is limited, so billing help matters. Patient support programs and financial assistance can lower out-of-pocket cost spikes for clinically useful tests, which helps keep access from slipping when coverage is narrow. That matters in a market where even a small cost gap can block uptake.
- Self-pay fills coverage gaps.
- Support tools reduce cost barriers.
- Access improves for needed tests.
Value-based diagnostic pricing
Myriad Genetics, Inc. prices tests on clinical utility, not lab volume, so high-complexity assays and companion diagnostics can carry higher value when they change treatment decisions.
This fits precision medicine, where payers want proof that a test improves care and cuts downstream costs.
Latest reported annual filings show revenue still driven by these evidence-backed tests, not commodity pricing.
- Price reflects treatment impact.
- Payer evidence drives access.
- Companion tests earn premium value.
Myriad's Real Price Is Set by Payers, Not Lists
Myriad Genetics, Inc. uses test-level pricing, so the real price is set by payer reimbursement, prior authorization, and contract status, not a single list price. In FY2025, realized price varied by assay, with coverage deciding both patient cost and company cash collected.
Self-pay support helps fill coverage gaps, but payer policy remains the main gatekeeper for volume and margin. Clinical utility still drives pricing power for higher-value tests.
| Price driver | Effect |
|---|---|
| Payer coverage | Sets realized price |
| Contract status | Changes patient cost |
| Clinical utility | Supports premium pricing |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.